SparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...
SparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...
SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for eye diseases, today announced that it has sold its ex vivo GIRK technology to Tenpoint Therapeutics.
SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...